Enteroendocrine cells and 5-HT availability are altered in mucosa of guinea pigs with TNBS ileitis

Jennifer R. O'Hara,1 Winnie Ho,1 David R. Linden,2 Gary M. Mawe,2 and Keith A. Sharkey1

1Gastrointestinal, Neuroscience, and Mucosal Inflammation Research Groups, Department of Physiology and Biophysics, University of Calgary, Calgary, Alberta, Canada T2N 4N1; and 2Department of Anatomy and Neurobiology, University of Vermont College of Medicine, Burlington, Vermont 05405

Submitted 26 February 2004 ; accepted in final form 30 June 2004


    ABSTRACT
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Enteroendocrine cells act as sensory transducers, releasing 5-HT and numerous peptides that are involved in regulating motility, secretion, and gut sensation. The action of mucosal 5-HT is terminated by a 5-HT reuptake transporter (SERT). In this study, we examined the hypothesis that ileitis leads to changes in enteroendocrine cell populations and mucosal 5-HT availability. Ileitis was induced in guinea pigs by intraluminal injection of 2,4,6-trinitrobenzenesulfonic acid and experiments were conducted 3, 7, and 14 days after treatment. The number of somatostatin, neurotensin, and 5-HT-immunoreactive cells increased at 3 and 7 days of ileitis, respectively, whereas no significant changes in the numbers of cholecystokinin, glucagon-like peptide-2, glucose-dependent insulinotropic peptide, and peptide YY-immunoreactive cells were observed. Chemical stimulation of the inflamed mucosa with sodium deoxycholic acid significantly increased 5-HT release compared with basal release. Mechanical stimulation of the mucosa potentiated the effect of the chemical stimuli at day 7. Epithelial SERT immunoreactivity was significantly reduced during the time course of inflammation. Thus changes in enteroendocrine cell populations and 5-HT availability could contribute to the altered motility and secretion associated with intestinal inflammation by disrupting mucosal signaling to enteric nerves involved in peristaltic and secretory reflexes.

inflammatory bowel disease; sensory transduction; motility; secretion; neurotensin; somatostatin


INTESTINAL MOTILITY AND SECRETION are initiated by luminal factors that activate intrinsic and extrinsic primary afferent nerves involved in peristaltic and secretory reflexes (21, 22). Enteroendocrine cells function as mucosal transducers to initiate reflex responses to mechanical and chemical stimulation of the mucosa. These cells transfer information regarding the contents of the lumen to nerve fibers lying in close proximity to the basolateral surface of the epithelium (21).

Bülbring and colleagues (6, 7) first proposed that a subset of enteroendocrine cells, known as enterochromaffin (EC) cells, release 5-HT in response to increases in intraluminal pressure. The 5-HT released from EC cells can stimulate both intrinsic and extrinsic primary afferent (sensory) neurons, via at least three different 5-HT receptors, 5-HT3, 5-HT4 and 5-HT1P (2, 28, 29, 46, 62). Activation of the 5-HT receptors is thought to depolarize afferent nerve terminals, which can lead to a variety of responses including the initiation of peristalsis, secretion, and gut sensation (2, 29, 46, 62). The actions of 5-HT are terminated by reuptake into epithelial cells via the high affinity 5-HT selective reuptake transporter (SERT) (12, 59). The epithelial SERT is identical to that found in the brain and enteric nervous system (32).

In addition to the 5-HT-containing EC cells, there are at least 14 other subpopulations of enteroendocrine cells (55, 56). The secretory products synthesized and released from the different subsets of enteroendocrine cells act as paracrine and/or endocrine mediators that modulate gastrointestinal function. In particular, neurotensin (N cells), somatostatin (Som; D cells), cholecystokinin (CCK; I cells), peptide tyrosine tyrosine (PYY; L cells), glucagon-like peptide-2 (GLP-2; L cells), and glucose-dependent insulinotropic peptide (GIP; K cells) have been reported to be involved in gastrointestinal motility, secretion, and/or cell proliferation (30, 33, 37, 39, 44, 57, 60).

Inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis, is associated with altered motility, secretion, and gut sensation (1, 10, 14, 34, 58). Therefore, changes in enteroendocrine cell populations and/or their secretory products could contribute to the symptoms associated with IBD by altering the luminal signaling to extrinsic and intrinsic primary afferent nerves. Previous studies (31, 45) have demonstrated increased numbers of EC cells and 5-HT content in animal models of colitis. An increased number of EC cells has also been demonstrated in human Crohn's ileitis (3). However, it is unknown whether the change in EC cell numbers during Crohn's ileitis is associated with an increase in the availability, release, and/or reuptake of 5-HT. Furthermore, changes in other types of enteroendocrine cells have yet to be systematically quantified in animal models of ileitis.

Therefore, the aim of this study was to examine mucosal 5-HT availability in an experimental model of ileitis in the guinea pig. To determine whether mucosal 5-HT availability is altered in inflammation, we used a 2,4,6-trinitrobenzenesulfonic acid (TNBS) model of ileitis and measured the number of 5-HT-immunoreactive EC cells, basal and stimulated release of 5-HT from EC cells, and mucosal 5-HT content. SERT immunoreactivity was examined to determine whether 5-HT reuptake and inactivation was affected by inflammation. We also quantified neurotensin, Som, CCK, PYY, GLP-2, and GIP-immunoreactive enteroendocrine cells in control and inflamed guinea pig ileum to examine the effect of inflammation on these enteroendocrine cell subpopulations. Our results suggest that there are significant changes to enteroendocrine cell populations in TNBS ileitis, and this is associated with altered mucosal 5-HT signaling in the inflamed ileum.


    MATERIALS AND METHODS
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Animal preparations. Male albino guinea pigs (Charles River, Montreal, Canada) weighing 200–300 g were housed in a temperature-controlled room. The animals were maintained on a normal 12:12-h light-dark cycle and were allowed access to food and water ad libitum. All methods used in this study were approved by the University of Calgary Animal Care Council and were carried out in accordance with the guidelines of the Canadian Council on Animal Care.

To induce inflammation in the ileum, fasted guinea pigs were anesthetized with halothane (induced at 4%, maintained on 2.5–3% in oxygen). A midline laparotomy was performed and the distal ileum was identified and exteriorized. TNBS (0.5 ml; Sigma-Aldrich; 30 mg/ml in 30% EtOH) was then injected into the lumen of the ileum ~5 cm from the ileocecal junction using a 30-gauge syringe. The ileum was replaced into the abdominal cavity and the incision was sutured. Three different control groups were also examined: the first group, vehicle controls, were assessed by injecting 0.5 ml of 30% EtOH into the distal ileum; the second group of controls were similarly treated with the exception that 0.5 ml physiological saline (0.9% NaCl) was injected into the distal ileum; and the third group of animals remained naïve.

Animals were maintained in a controlled environment for 3, 7, or 14 days after surgery. At the time of tissue collection, animals were anesthetized with an overdose of pentobarbital sodium and exsanguinated. The distal ileum was then removed and used for experimental studies.

Assessment of inflammation. Inflammation induced by administration of TNBS into the lumen of the small intestine has previously been demonstrated as inducing a transmural inflammation analogous to human Crohn's disease (43). The TNBS acts as a hapten, eliciting a Th1-mediated immune response characterized by the presence of proinflammatory cytokines that are also involved in the development of spontaneous Crohn's disease (43, 54). The severity of ileitis was assessed by measuring changes in the weight of the animals and examining macroscopic damage to the mucosa. Animals were weighed before administration of TNBS, EtOH, or saline and daily after surgery. After animals were euthanized, the ileum was removed, opened along the mesenteric border, and examined macroscopically. The criteria used for scoring gross morphological damage have been described previously (38, 40, 41). Briefly, the total score of mucosal damage included the presence and severity of adhesions (score 0–2); the maximum thickness of the ileal wall (in mm); and the extent of inflammation, ulceration, and hyperemia (score 0–10).

Immunohistochemistry. Ileal segments to be used for immunohistochemistry were opened along the mesenteric border, stapled flat with mucosa side up, and fixed overnight at 4°C in Zamboni's fixative (2% paraformaldehyde, 15% picric acid, pH 7.4). Samples were then transferred to 20% sucrose in PBS overnight at 4°C. Transverse and circumferential segments from each animal were embedded with the mucosa oriented in the same direction, in OCT compound (Miles, Elkhardt, IN). Sections of ileum (12 µm) were cut on a cryostat, thaw-mounted onto poly-D-lysine (PDL)-coated slides, and stored at –20°C until use.

Changes in enteroendocrine cell populations and SERT expression were examined in sections of saline-treated control and inflamed ileum at 3, 7, and 14 days after the administration of saline or TNBS. EtOH-treated controls and naive animals were examined at 3 and 7 days after injection of EtOH or fasting, respectively. Tissue sections were washed with PBS containing 0.1% Triton X-100 (3 x 10 min), followed by incubation in primary antisera (Table 1) for 48 h at 4°C. The sections were washed again with PBS containing 0.1% Triton X-100 (3 x 10 min) and incubated with secondary antisera for 2 h at room temperature. Secondary antisera included Cy3-conjugated donkey anti-rabbit IgG (1:100; Jackson) and Cy3-conjugated donkey anti-mouse IgG (1:100; Biocan). The sections were subsequently washed in PBS (3 x 5 min). The stained sections were coverslipped with bicarbonate-buffered glycerol and examined with a Zeiss Axioplan fluorescence microscope. Photographs were taken by using a digital imaging system consisting of a digital camera (Sensys; Photometrics, Tucson, Arizona) and image analysis software (V for Windows; Digital Optics, Auckland, New Zealand). Photographs of SERT immunofluorescence were taken at the same exposure time and magnification (x40).


View this table:
[in this window]
[in a new window]
 
Table 1. Primary antibodies

 
Controls consisted of liquid-phase preabsorption of primary antisera with cognate peptides or 5-HT (10 nmol/ml diluted antisera) and omission of the primary antisera. In all cases, immunoreactivity was abolished by these procedures.

To quantify the number of enteroendocrine cells, sections of ileum adjacent to sites of ulceration and severe inflammation were used to readily visualize intact villi. The number of 5-HT-positive EC cells per villi and associated crypts were counted. The mean number of cells per 10 villus-crypt units in each section was calculated and five sections per animal were included. Separate tissue sections were stained with hematoxylin and eosin, followed by dehydration, so that the total number of epithelial cells in a given region could be examined. Random sections of saline-treated control and inflamed ileum were examined, and the average number of stained nuclei per villi was counted.

Measurement of 5-HT content in the ileum. A segment of fresh ileum (1 x 5 cm) was removed, and the mucosa was gently scraped off, collected, and weighed. The mucosal samples were homogenized in 0.2 M perchloric acid (10 µl/mg mucosa) and centrifuged at 10,000 g for 5 min at 4°C. The supernatant was filtered through a 0.22-µm filter, neutralized with equal volumes of 1 M borate buffer (pH 9.25) and centrifuged at 10,000 g for 1 min. The 5-HT content of an aliquot of each sample was analyzed with an enzyme immunoassay kit used according to the manufacturer's instructions (Beckman Coulter, Fullerton, CA).

Measurement of mucosal 5-HT release in the ileum. The ileum was opened along the mesentery and cut into six segments (1 x 0.5 cm). The segments were pinned flat, mucosal side up, in a Sylgard-coated six-well dish containing 37°C HEPES solution (in mM: 110 NaCl; 5.4 KCl; 1.8 CaCl2 2 H20; 1 MgCl 6 H20, 60 sucrose, 5 glucose, 20 HEPES). After a 15-min incubation period, the bathing solution was replaced by 3 ml of normal HEPES solution or 3 ml of the bile acid (5 mM sodium deoxycholic acid) (47). To mechanically stimulate the mucosa, segments of ileum were gently stroked in a circumferential direction with a rounded glass probe (diameter ~2 mm) at a rate of 8 strokes/min for a total of 15 min (31). To represent the contents of the small intestine, a combination of mechanical stimulation of the mucosa and bile acid was applied. The mucosal stimulation is analogous to the passage of the fluid contents through the lumen, whereas bile acids are absorbed as the contents move through the small intestine. Basal levels of 5-HT release were determined by leaving preparations undisturbed in the bathing solution for 15 min. The 5-HT released into the bathing solution was measured with an enzyme immunoassay kit used according to the manufacturer's instructions (Beckman Coulter, Fullerton, CA).

Data analysis. The data are presented as means ± SE for n animals. Intensity of SERT immunofluorescence was measured by using the Scion Image program, and statistical comparisons were conducted with Graphpad Prism software (Version 3.03, GraphPad Software, San Diego, CA). Comparisons between three or more groups were done with a one-way ANOVA followed by a Dunnett's multiple comparison test. Data with a nonparametric distribution were analyzed by a Kruskal-Wallis Test followed by a Dunnett's multiple comparison test. P < 0.05 was considered statistically significant.


    RESULTS
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
TNBS-induced inflammation. Administration of TNBS into the lumen of the ileum caused regional inflammation characterized by ulceration, adhesions, hyperemia, and changes to mucosal architecture that were similar to previously described animal models of TNBS-induced ileitis (38, 40, 41). Initially after surgery, TNBS-treated guinea pigs lost weight, but began to regain it after 1–2 days. In contrast, saline-treated control animals remained at a stable weight or gained weight after surgery (Fig. 1A). The macroscopic damage scores from saline-treated controls were not significantly different at 3, 7, and 14 days after injection of saline; therefore, the data at each time point were pooled. Macroscopic damage scores obtained at 3, 7, and 14 days after administration of TNBS demonstrated significant mucosal damage on day 3. At this time, muscle hypertrophy and destruction of the mucosa were evident. By the seventh day of inflammation, the extent of mucosal damage was reduced and villus structure was restored, indicating recovery was in progress; however, muscle thickening and minor adhesions were still evident (Fig. 1B; *P < 0.05 compared with saline-treated controls) (saline-treated controls, n = 12; EtOH-treated controls, n = 6; 3-day TNBS n = 6; 7-day TNBS, n = 6; 14-day TNBS, n = 6). At 14 days after injection of TNBS, macroscopic evaluation of the mucosa revealed no significant difference from control tissue.



View larger version (16K):
[in this window]
[in a new window]
 
Fig. 1. A: 2,4,6-trinitrobenzenesulfonic acid (TNBS)-treated animals initially lost weight after injection of TNBS but began to gain weight 1–2 days after surgery. In contrast, saline-treated animals remained at a stable weight after surgery. B: macroscopic damage scores were significantly greater at 3 and 7 days of inflammation compared with saline and EtOH-treated controls. *P < 0.05 compared with controls (means ± SE); Kruskal-Wallis test followed by a Dunnett's multiple comparison test; saline-treated controls, n = 12; EtOH-treated controls, n = 6; 3-day TNBS n = 6; 7-day TNBS, n = 6; 14-day TNBS, n = 6.

 
Examination of tissue from the EtOH-treated animals demonstrated no significant difference in macroscopic appearance of the mucosa at 3 and 7 days after injection of EtOH and the data from each time point were pooled. Macroscopic damage scores of the EtOH-treated tissue revealed no difference in muscle thickness or mucosal architecture compared with saline-treated controls (Fig. 1B) or naive controls (data not shown).

EC cell numbers. 5-HT immunoreactive EC cells were quantified in sections of control and inflamed ileum. The mean number of EC cells distributed throughout 10 villus-crypt units in each section was calculated (Fig. 2A). The number of EC cells increased over the first 7 days of inflammation. At 7 days of inflammation, the number of EC cells was significantly greater compared with saline-treated controls (Fig. 2B; P = 0.01) (saline-treated controls, n = 12; 3-day TNBS, n = 6; 7-day TNBS, n = 6; 14-day TNBS, n = 6). To determine whether a general increase in epithelial cell numbers contributed to the increase in EC cell numbers, a hematoxylin and eosin stain was performed. The average number of epithelial cells per villi was not significantly different in the saline-treated control tissue compared with the TNBS-treated tissue (data not shown). Fourteen days after the administration of TNBS, the number of EC cells was not significantly different from the saline-treated controls. In addition, the number of 5-HT-immunoreactive EC cells in the EtOH-treated animals (n = 6) and naive controls (n = 3) was comparable to the number of cells in the saline-treated controls (data not shown).



View larger version (46K):
[in this window]
[in a new window]
 
Fig. 2. A: representative micrographs demonstrating 5-HT-immunoreactive enterochromaffin (EC) cells in sections of control vs. 3-, 7-, and 14-day inflamed ileum. Scale bar = 50 µm. B: number of 5-HT-immunoreactive EC cells in saline-treated control tissue did not differ at 3, 7, and 14 days; therefore, the data from each time point are pooled. The number of EC cells per 10 villus-crypt units increased over the first 7 days of ileitis and returned to baseline levels by day 14. *P = 0.01 compared with control (means ± SE); one-way ANOVA followed by Dunnett's multiple comparison test (saline-treated controls, n = 12; 3-day TNBS, n = 6; 7-day TNBS, n = 6; 14-day TNBS, n = 6).

 
Mucosal 5-HT content. An increase in the number of EC cells, the site of synthesis, and storage of 5-HT, could lead to an increase in the mucosal content of 5-HT. 5-HT content in control and inflamed guinea pig ileum was measured by enzyme immunoassay (Fig. 3A; saline-treated controls, n = 6; 3-day TNBS, n = 6; 7-day TNBS, n = 6). The 5-HT content of the ileum was expressed as a function of wet weight of mucosa, as well as a function of area (cm2) of ileum to account for the infiltration of inflammatory mediators. In both parameters, there was no significant difference in 5-HT content between the TNBS-treated tissues and control preparations.



View larger version (23K):
[in this window]
[in a new window]
 
Fig. 3. Mucosal 5-HT content was expressed as a function of wet weight of mucosa (A) and as a function of length of ileum (B). In both parameters, no significant difference in 5-HT content was observed in the inflamed ileum (3-day TNBS, n = 6; 7-day TNBS, n = 6) vs. the saline-treated controls (n = 6). C: 5-HT release into the bathing medium was significantly increased in response to chemical and mechanical stimulation of the mucosa (as described in MATERIALS AND METHODS) compared with basal release in saline-treated controls (white bars; basal, n = 7; bile acid, n = 6; mechanical, n = 7; combined stimuli, n = 6). In the 3-day inflamed ileum (black bars; basal, n = 7; bile acid, n = 8; mechanical, n = 8; combined stimuli, n = 9), chemical stimulation alone and a combination of mechanical and chemical stimulation significantly increased 5-HT release compared with basal release. *P < 0.05 compared with basal release (means ± SE), one-way ANOVA followed by Dunnett's multiple comparison test. Bile acid alone and the combined stimuli resulted in a significantly greater increase in 5-HT release from the 3-day inflamed tissue compared with the saline-treated control tissue in response to the same stimuli. {delta}P < 0.05 compared with saline-treated controls. In the 7-day inflamed ileum (gray bars; basal, n = 8; bile acid, n = 6; mechanical, n = 6; combined stimuli, n = 6), the bile acid alone and the combined chemical and mechanical stimulation of the mucosa significantly increased 5-HT release compared with basal release. *P < 0.05 compared with basal release. The combined stimuli resulted in a significantly greater increase in 5-HT release from the 7-day inflamed tissue compared with the saline-treated control tissue. {delta}P < 0.05 compared with saline-treated controls.

 
5-HT release. To test whether the increase in the number of EC cells was associated with an increase in the secretion of 5-HT, we measured 5-HT release from the mucosa in isolated segments of ileum under basal and stimulated conditions. Sodium deoxycholic acid and mechanical stroking were used to stimulate the release of 5-HT from EC cells. Under basal conditions, the amount of 5-HT released did not differ between saline-treated control and inflamed tissue (Fig. 3; basal release: saline-treated control, n = 7; 3-day TNBS; n = 7; 7-day TNBS, n = 8). The release of 5-HT from saline-treated control tissue was significantly increased in response to chemical (n = 6) and mechanical stimuli (n = 7), as well as a combination of the two stimuli (n = 6). In tissues from TNBS-treated animals, 5-HT release at 3 days was significantly increased in response to the bile acid alone (n = 8), and in combination with the mechanical stimulus (n = 9) compared with basal conditions. 5-HT release in response to the combined stimuli was significantly greater in the 3-day ileum vs. the saline-treated control ileum (Fig. 3; P < 0.05). However, mechanical stimulation alone (n = 8) did not significantly alter 5-HT release. At 7 days after administration of TNBS, 5-HT release was significantly increased in response to bile acid (n = 6) compared with basal 5-HT release. Mechanical stimulation (n = 6) failed to elicit a response in the 7-day inflamed tissue compared with basal 5-HT release. However, the mechanical stimulus appeared to potentiate the effect of the bile acid (n = 6). 5-HT release in response to the combined stimuli was significantly greater in the 7-day inflamed tissue compared with the saline-treated controls (Fig. 3; P < 0.05).

5-HT reuptake transporter. The 5-HT reuptake transporter (SERT) removes 5-HT from the extracellular space by transporting 5-HT into epithelial cells; therefore, decreased reuptake of 5-HT may contribute to the increased 5-HT release observed. We examined the possibility that SERT is downregulated in the inflamed ileum. To determine whether the expression of SERT was altered during inflammation, SERT protein was evaluated by immunohistochemistry. In the saline-treated control ileum, relatively intense SERT immunoreactivity was observed throughout the epithelial cell layer and in the myenteric plexus. Compared with that of control tissue, mucosal SERT immunoreactivity was reduced at 3 days of inflammation and was virtually absent by day 7 (Fig. 4A). At 14 days after injection of TNBS, SERT immunoreactivity in the mucosa had returned to control levels. SERT expression in the myenteric plexus was similar in the ileum of saline and TNBS-treated guinea pigs (Fig. 4B). The intensity of SERT immunoreactivity in the saline-treated control and inflamed ileum were quantitatively compared, and the mean intensity of immunofluorescence in the inflamed mucosa was significantly reduced compared with saline-treated control levels (Fig. 4C; P < 0.05).



View larger version (50K):
[in this window]
[in a new window]
 
Fig. 4. A: representative micrographs comparing 5-HT reuptake transporter (SERT) immunoreactivity in saline-treated control and inflamed ileum. Exposure times are the same in all images. SERT immunoreactivity is decreased at 3 days of inflammation and is virtually absent by day 7. SERT expression at 14 days has returned to control levels. Scale bar = 50 µm. B: in contrast, SERT immunoreactivity is similar in the myenteric plexus of saline-treated control and inflamed ileum (arrows). C: intensity of mucosal SERT immunofluorescence was measured by using Scion Image. The mean intensity of staining was significantly lower in the inflamed ileum at 3 and 7 days compared with control. At 14 days of inflammation, the intensity of SERT immunoreactivity had returned to baseline levels. *P < 0.05 (means ± SE); one-way ANOVA followed by Dunnett's multiple comparison test.

 
Enteroendocrine cell numbers. To determine whether the changes in enteroendocrine cell numbers were limited to the 5-HT-containing EC cell type, several other subpopulations of enteroendocrine cells in saline-treated control vs. inflamed guinea pig ileum were assessed by immunohistochemistry. The enteroendocrine cells were quantified as described for the 5-HT-containing EC cells. The numbers of PYY-, GIP-, GLP-2-, and CCK-containing enteroendocrine cells were not significantly different in the ileum of the saline-treated control vs. inflamed ileum. However, the numbers of neurotensin and Som-immunoreactive enteroendocrine cells were significantly increased at 3 days of inflammation compared with saline-treated guinea pigs (Fig. 5; P < 0.05) (neurotensin: saline-treated controls, n = 11; 3-day TNBS, n = 4; 7-day TNBS, n = 4; 14-day TNBS, n = 4; Som: saline-treated controls, n = 12; 3-day TNBS, n = 6; 7-day TNBS, n = 6; 14-day TNBS, n = 5). On days 7 and 14, the number of neurotensin and Som-containing cells were not significantly different from control values.



View larger version (69K):
[in this window]
[in a new window]
 
Fig. 5. Quantitative comparison of enteroendocrine cell numbers in saline-treated control and inflamed ileum. A: the number of somatostatin (Som)-immunoreactive D cells was significantly increased at day 3 of inflammation compared with saline-treated controls. Cell numbers had returned to baseline levels by day 14. *P = 0.04 (means ± SE); one-way ANOVA followed by Dunnett's multiple comparison test (saline-treated controls, n = 12; 3-day TNBS, n = 6; 7-day TNBS, n = 6; 14-day TNBS, n = 5). Representative micrograph of Som-immunoreactive D cells (which also shows the Som-immunoreactive nerves in the mucosa). Scale bar = 50 µm. B: number of neurotensin (NT)-immunoreactive N cells increased at day 3 of inflammation compared with saline-treated control values and returned to baseline levels at day 7. *P = 0.007 (means ± SE); saline-treated controls, n = 11; 3-day TNBS, n = 4; 7-day TNBS, n = 4; 14-day TNBS, n = 4. Representative micrograph of neurotensin-immunoreactive N cells. Scale bar = 50 µm.

 

    DISCUSSION
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
The aim of this investigation was to examine enteroendocrine cell populations and determine whether mucosal 5-HT availability is altered in the inflamed small intestine. Data from this study demonstrate that TNBS-induced ileitis is associated with an increase in the number of 5-HT-immunoreactive EC cells, a decrease in mucosal SERT immunoreactivity, and an increase in mucosal 5-HT release. We have also shown that the epithelial changes are not limited to the 5-HT-immunoreactive enteroendocrine cell type, because changes in the number of neurotensin-immunoreactive N cells and Som-immunoreactive D cells during inflammation were also demonstrated. However, no significant changes to the GIP-, GLP-2-, CCK- and PYY-immunoreactive enteroendocrine cell populations were observed.

The majority of the body's 5-HT is localized to secretory granules of EC cells (23), and previous studies (20, 31, 45) have demonstrated that the number of 5-HT-immunoreactive EC cells is increased in human and animal models of the inflamed large intestine. Our data from the small intestine are similar to the TNBS-induced colitis model in that we observed an increased number of EC cells in TNBS-induced ileitis. The EC cell hyperplasia observed in previous studies (31, 45) was associated with an increase in mucosal 5-HT content. In the TNBS model of colitis, Linden et al. (31) demonstrated a decrease in 5-HT content per unit wet weight of tissue. However, 5-HT content increased when expressed as a function of unit length of colon. In contrast, Magro et al. (35) demonstrated a decrease in tissue levels of 5-HT in both ulcerative colitis and Crohn's colitis patients. In the present study, no significant change in 5-HT content was observed in the inflamed small intestine.

Previous studies (5) examining the colonic mucosa of patients with irritable bowel syndrome (IBS) have demonstrated an increased number of 5-HT-immunoreactive EC cells vs. controls, which was apparently associated with a lower colonic mucosal 5-HT content in the IBS patients. Thus an increased number of EC cells may not directly correlate with an increase in mucosal 5-HT content. This could be due to a number of factors including decreased synthesis of 5-HT due to alterations in tryptophan hydroxylase, the rate-limiting enzyme in the synthesis of 5-HT. This is supported in a study by Coates et al. (13), demonstrating reduced 5-HT content that correlated with significantly lower levels of tryptophan hydroxylase in the colonic mucosa of patients with ulcerative colitis and IBS, whereas EC cell numbers were decreased only in patients with severe ulcerative colitis. The incorporation of sites of inflammation and ulceration in the tissue samples assessed could also contribute to the lower 5-HT content observed in the present study. The areas of inflammation often consisted of mucosal damage with destruction of villi, particularly at 3 days of inflammation. Consequently, lower mucosal 5-HT content may be observed.

Regional differences in the intestinal segment being examined could also contribute to any variation observed in the TNBS model of ileitis vs. the TNBS model of colitis. It appears that the time course and severity of the inflammatory response to TNBS in the ileum differs from that in the colon (36, 42, 43). One possible explanation is the variation in the bacterial flora throughout the gastrointestinal tract. The small intestine is a relatively sterile environment compared with the extensive bacterial load in the colon (50) and this may influence the time course and severity of inflammation. Furthermore, a recent study (17) demonstrated the expression of toll-like receptors (TLRs), involved in the recognition of bacterial components on murine and human enteroendocrine cell lines. The same group also reported the expression of TLR1, TLR2, and TLR4 by 5-HT-immunoreactive EC cells in primary human intestinal tissue sections. Further studies examining the effect of bacteria and on the 5-HT signaling system may determine whether the intestinal flora has a role in the inconsistencies between the ileum and colon.

EC cells, acting as mucosal transducers, release 5-HT in response to various luminal stimuli including distortion of the mucosa, bile acids, nutrients, and toxins (24, 46, 47, 51). Therefore, EC cell hyperplasia during inflammation could lead to enhanced release of 5-HT in response to luminal stimuli. This is supported by the observation that the maximum increase in both EC cell numbers and stimulated 5-HT release was at 7 days after injection of TNBS. At the 7-day time point, mechanical stimulation of the mucosa appeared to potentiate the effect of the bile acid. The amount of 5-HT released from the inflamed tissue was significantly greater than the amount released from the saline-treated control tissue in response to the same stimuli. In contrast to the 7-day inflamed tissue, potentiation was not observed at 3 days of inflammation. It is not yet known why this is the case; however, we speculate that the degree of inflammation at 3 days precludes the maximum stimulatory effect that is observed at 7 days. This may be due to the extensive infiltration of inflammatory mediators at the more acute stage of inflammation.

Interestingly, release of 5-HT in response to mechanical stimulation of the inflamed mucosa was not significantly different from the saline-treated controls, whereas the mechanical stimulation significantly increased 5-HT release compared with basal release in the control ileum. It should be emphasized that the release of 5-HT from EC cells involves a complex mechanism of regulation. EC cells appear to be endowed with a number of different receptors including stimulatory {beta}-adrenoceptors, cholinergic and 5-HT3 receptors, as well as inhibitory purinoceptors, {alpha}2-adrenoceptors, GABA, histamine H3, and 5-HT4 receptors (48, 49). Mechanical stimulation of the mucosa may stimulate extrinsic and intrinsic primary afferent nerves that contain sensory elements activated by stretch or mechanical forces (15, 52). Modulation of neurotransmitter release during inflammation could contribute to the changes in 5-HT release from EC cells in response to mechanical stimulation of the mucosa. Furthermore, mechanical stimulation can release additional mediators from epithelial cells and EC cells that have a paracrine or autocrine regulation of 5-HT release (15). For instance, stroking of the mucosa stimulates the release of ATP from epithelial and EC cells that can subsequently stimulate purinoceptors located on the EC cells (15). It is possible that intestinal inflammation alters the mechanically stimulated release of other mediators, such as ATP, subsequently leading to aberrant 5-HT release.

An additional factor that could contribute to the observed increase in 5-HT release during inflammation is a decreased reuptake of 5-HT by SERT. Enzymes known to metabolize 5-HT include monoamine oxidase and glucuronyl transferase, both of which are located intracellularly (4). At physiological pH, 5-HT is highly charged and is unable to readily cross the plasma membrane (12). Therefore, in order for the actions of 5-HT to be terminated, it must be transported into the cells that possess the catabolic enzymes. A decreased ability of cells to take up 5-HT could lead to an increased concentration of 5-HT in the extracellular space and prolonged exposure to the 5-HT receptors located on primary afferent nerves. Our results indicate that reuptake of 5-HT may be decreased during inflammation as SERT immunoreactivity was virtually absent by day 7 of inflammation. The observation that SERT expression is downregulated during inflammation is consistent with previous studies in a guinea pig TNBS model of colitis (31), human ulcerative colitis (13), and IBS (13).

Collectively, these observations suggest that during ileitis there is an increased availability of 5-HT to primary afferent nerves that are located adjacent to the basolateral membrane of the epithelium. The increased availability is most likely due to EC cell hyperplasia and decreased reuptake of 5-HT, leading to increased 5-HT release into the extracellular space. At this time, the physiological role of 5-HT in TNBS-induced ileitis is unknown. However, 5-HT has been demonstrated to activate intrinsic and extrinsic primary afferent nerves involved in the peristaltic and secretory reflexes (2, 2527, 29, 46). Therefore, the increased release of 5-HT could enhance activation of these primary afferent nerves, thereby contributing to increased motility and/or secretion during inflammation. Conversely, excessive amounts of 5-HT could lead to receptor desensitization and a reduced activation of the primary afferent terminals leading to decreased motility and/or secretion. This concept is supported in the study by Chen et al. (11) who demonstrated alternating periods of diarrhea and constipation in SERT knockout mice. Therefore, depending on the state of the receptor, the increased availability of 5-HT during inflammation could contribute to the altered motility and secretion associated with IBD. Furthermore, Martinolle et al. (36) examined longitudinal and circular muscle contractile responses to serotonergic receptor stimulation in guinea pigs with TNBS-induced ileitis. In the circular muscle preparations from the inflamed animals, the contractile response to exogenously applied 5-HT was significantly reduced compared with controls. They suggest that the hyporesponsiveness of the circular muscle layer could be due to nerve and/or muscle receptor desensitization that is, in part, caused by the excessive release of inflammatory mediators.

Whereas 5-HT has been emerging as an important mediator in IBD, other enteroendocrine cells and their respective secretory products have also been demonstrated to undergo changes during inflammation. In the colon of patients with IBD, as well as in a Schistosoma mansoni model of inflammation, a reduced number of Som-containing D cells has been demonstrated (18, 61). In addition, there is evidence that neurotensin content in colonic inflammation is increased and the neurotensin antagonist, SR-48,692, inhibits toxin A-induced colitis (9). This has led to the hypothesis that neurotensin is a proinflammatory peptide in colonic inflammation (9). Mice with a nonfunctional T-cell receptor spontaneously develop inflammation of the colon, and these mice demonstrate a decreased expression of neurotensin, cholecystokinin, and 5-HT-containing cells (53). Furthermore, in a DSS-induced model of mouse colitis, GLP-2 content in the colon was reduced by 50% compared with control tissue (19).

In the present study, we demonstrated an increase in the number of neurotensin-immunoreactive N cells and Som-immunoreactive D cells at day 3 of inflammation, whereas the maximal increase in 5-HT-immunoreactive EC cells occurred at 7 days of inflammation. There were no significant changes observed in the GIP, GLP-2, CCK, or PYY-immunoreactive enteroendocrine cells at any time point of inflammation. Taken together, these observations indicate that the changes in enteroendocrine cell populations are not due to a general increase or decrease in total epithelial cell number; instead, it suggests that there is a complex regulation of enteroendocrine cell development and differentiation, and this process may be altered during inflammation.

The functional implication of the increased numbers of N and D cells are unknown; however, previous studies (9) have demonstrated elevated levels of neurotensin during toxin A- induced intestinal inflammation. The increased levels of neurotensin preceded the toxin A-induced changes in secretion and mucosal permeability (9). Therefore, the increased number of N cells could lead to increased levels of the proinflammatory peptide, thereby contributing to the altered secretion and mucosal permeability associated with inflammation. In contrast, Som is an inhibitory anti-inflammatory peptide that depresses the inflammatory response to various stimuli (8). The altered number of D cells may be a compensatory mechanism that leads to increased mucosal Som levels in an attempt to limit the extent of the inflammatory response elicited by the increased levels of neurotensin.

In conclusion, data from the present study indicate that the cellular structures responsible for the synthesis, storage, and secretion of 5-HT, neurotensin, and Som are altered during ileitis. Given the role of enteroendocrine cells in mucosal sensory transduction (6, 7, 22), the inflammation-induced alterations in the number of these cells could lead to aberrant mucosal signaling to extrinsic and intrinsic primary afferent nerves during inflammation, thereby contributing to the altered motility and secretion that is associated with IBD. Therefore, it is possible that 5-HT, Som, and/or neurotensin signaling pathways could provide useful therapeutic targets for IBD. However, further examination of their role in the inflammatory process is required.


    GRANTS
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
This work was supported by National Institutes of Health Grants F32-DK-60382 (to D. R. Linden), NS-26995 (to G. M. Mawe), and DK-62267 (to G. M. Mawe), and a grant from the Crohn's and Colitis Foundation of Canada (to K. A. Sharkey and G. M. Mawe). K. A. Sharkey is an Alberta Heritage Foundation for Medical Research Medical Scientist.


    ACKNOWLEDGMENTS
 
We thank Cathy MacNaughton for assistance with these studies, Marja Van Sickle for comments on the manuscript, Dr. Randy Blakely for providing the SERT antiserum, Dr. Alison Buchan for the GIP antiserum, and the late Dr. John Walsh for the CCK and PYY antisera.


    FOOTNOTES
 

Address for reprint requests and other correspondence: K. Sharkey, Dept. of Physiology and Biophysics, Univ. of Calgary, 3330 Hospital Drive NW, Calgary, AB Canada T2N 4N1 (E-mail:ksharkey{at}ucalgary.ca)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


    REFERENCES
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 

  1. Asfaha S, Bell CJ, Wallace JL, and MacNaughton WK. Prolonged colonic epithelial hyporesponsiveness after colitis: role of inducible nitric oxide synthase. Am J Physiol Gastrointest Liver Physiol 276: G703–G710, 1999.[Abstract/Free Full Text]
  2. Bertrand PP, Kunze WA, Furness JB, and Bornstein JC. The terminals of myenteric intrinsic primary afferent neurons of the guinea-pig ileum are excited by 5-hydroxytryptamine acting at 5-hydroxytryptamine-3 receptors. Neuroscience 101: 459–469, 2000.[CrossRef][ISI][Medline]
  3. Bishop AE, Pietroletti R, Taat CW, Brummelkamp WH, and Polak JM. Increased populations of endocrine cells in Crohn's ileitis. Virchows Arch A Pathol Anat Histopathol 410: 391–396, 1987.[ISI][Medline]
  4. Blaschko H and Levine WG. Metabolism of indolealkylamines. In: 5-Hydroxytryptamine and Related Indolealkylamines, edited by Erspamer V. Berlin: Springer-Verlag, 1966, p. 212–239.
  5. Bose M, Nickols C, and Greenwald S. 5-Hydroxytryptamine (5-HT) levels in colonic mucosa in irritable bowel syndrome (IBS): assessment by high performance liquid chromatography (HPLC) (Abstract). Gut 48: A57, 2001.
  6. Bülbring E and Crema A. The release of 5-hydroxytryptamine in relation to pressure exerted on the intestinal mucosa. J Physiol 146: 18–28, 1959.[ISI]
  7. Bülbring E and Lin R. The effect of intraluminal application of 5-hydroxytryptamine and 5-hydroxytryptophan on peristalsis; the local production of 5-HT and its release in relation to intraluminal pressure and propulsive activity. J Physiol 140: 381–407, 1958.[ISI][Medline]
  8. Carlton SM, Du J, Davidson E, Zhou S, and Coggeshall RE. Somatostatin receptors on peripheral primary afferent terminals: inhibition of sensitized nociceptors. Pain 90: 233–244, 2001.[CrossRef][ISI][Medline]
  9. Castagliuolo I, Wang CC, Valenick L, Pasha A, Nikulasson S, Carraway RE, and Pothoulakis C. Neurotensin is a proinflammatory neuropeptide in colonic inflammation. J Clin Invest 103: 843–849, 1999.[Abstract/Free Full Text]
  10. Chang L, Munakata J, Mayer EA, Schmulson MJ, Johnson TD, Bernstein CN, Saba L, Naliboff B, Anton PA, and Matin K. Perceptual responses in patients with inflammatory and functional bowel disease. Gut 47: 497–505, 2000.[Abstract/Free Full Text]
  11. Chen JJ, Li Z, Pan H, Murphy DL, Tamir H, Koepsell H, and Gershon MD. Maintenance of serotonin in the intestinal mucosa and ganglia of mice that lack the high-affinity serotonin transporter: abnormal intestinal motility and the expression of cation transporters. J Neurosci 21: 6348–6361, 2001.[Abstract/Free Full Text]
  12. Chen JX, Pan H, Rothman TP, Wade PR, and Gershon MD. Guinea pig 5-HT transporter: cloning, expression, distribution, and function in intestinal sensory reception. Am J Physiol Gastrointest Liver Physiol 275: G433–G448, 1998.[Abstract/Free Full Text]
  13. Coates MD, Mahoney CR, Linden DR, Sampson JE, Chen J, Blaszyk H, Crowell MD, Sharkey KA, Gershon MD, Mawe GM, and Moses PL. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 126: 1657–1664, 2004.[ISI][Medline]
  14. Collins SM. The immunomodulation of enteric neuromuscular function: implications for motility and inflammatory disorders. Gastroenterology 111: 1683–1699, 1996.[ISI][Medline]
  15. Cooke HJ, Wunderlich J, and Christofi FL. "The force be with you": ATP in gut mechanosensory transduction. News Physiol Sci 18: 43–49, 2003.[ISI][Medline]
  16. Damholt AB, Kofod H, and Buchan AM. Immunocytochemical evidence for a paracrine interaction between GIP and GLP-1-producing cells in canine small intestine. Cell Tissue Res 298: 287–293, 1999.[CrossRef][ISI][Medline]
  17. Dave S, Liu S, Bogunovic M, and Plevy S. Toll-like receptors on enteroendocrine cells: role and function in gut homeostasis (Abstract). Gastroenterology 126, Suppl 2: A-573. 2004.
  18. De Jonge F, Van Nassauw L, De Man JG, De Winter BY, Van Meir F, Depoortere I, Peeters TL, Pelckmans PA, Van Marck E, and Timmermans JP. Effects of Schistosoma mansoni infection on somatostatin and somatostatin receptor 2A expression in mouse ileum. Neurogastroenterol Motil 15: 149–159, 2003.[ISI][Medline]
  19. Drucker DJ, Yusta B, Boushey RP, DeForest L, and Brubaker PL. Human [Gly2]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis. Am J Physiol Gastrointest Liver Physiol 276: G79–G91, 1999.[Abstract/Free Full Text]
  20. El Salhy M, Danielsson A, Stenling R, and Grimelius L. Colonic endocrine cells in inflammatory bowel disease. J Intern Med 242: 413–419, 1997.[CrossRef][ISI][Medline]
  21. Furness JB, Kunze WAA, and Clerc N. Nutrient Tasting and Signaling Mechanisms in the Gut. II. The intestine as a sensory organ: neural, endocrine, and immune responses. Am J Physiol Gastrointest Liver Physiol 277: G922–G928, 1999.[Abstract/Free Full Text]
  22. Gershon MD. Roles played by 5-hydroxytryptamine in the physiology of the bowel. Aliment Pharmacol Ther 13, Suppl 2: 15–30, 1999.
  23. Gershon MD. Plasticity in serotonin control mechanisms in the gut. Curr Opin Pharmacol 3: 600–607, 2003.[CrossRef][ISI][Medline]
  24. Grider JR, Kuemmerle JF, and Jin JG. 5-HT released by mucosal stimuli initiates peristalsis by activating 5-HT4/5-HT1p receptors on sensory CGRP neurons. Am J Physiol Gastrointest Liver Physiol 270: G778–G782, 1996.[Abstract/Free Full Text]
  25. Grundy D, Blackshaw LA, and Hillsley K. Role of 5-hydroxytryptamine in gastrointestinal chemosensitivity. Dig Dis Sci 39: 44S–47S, 1994.[Medline]
  26. Hillsley K and Grundy D. Sensitivity to 5-hydroxytryptamine in different afferent subpopulations within mesenteric nerves supplying the rat jejunum. J Physiol 509: 717–727, 1998.[Abstract/Free Full Text]
  27. Hillsley K, Kirkup AJ, and Grundy D. Direct and indirect actions of 5-hydroxytryptamine on the discharge of mesenteric afferent fibres innervating the rat jejunum. J Physiol 506: 551–561, 1998.[Abstract/Free Full Text]
  28. Jin JG, Foxx-Orenstein AE, and Grider JR. Propulsion in guinea pig colon induced by 5-hydroxytryptamine (HT) via 5-HT4 and 5-HT3 receptors. J Pharmacol Exp Ther 288: 93–97, 1999.[Abstract/Free Full Text]
  29. Kirchgessner AL, Tamir H, and Gershon MD. Identification and stimulation by serotonin of intrinsic sensory neurons of the submucosal plexus of the guinea pig gut: activity-induced expression of Fos immunoreactivity. J Neurosci 12: 235–248, 1992.[Abstract]
  30. Liddle RA. Cholecystokinin cells. Annu Rev Physiol 59: 221–242, 1997.[CrossRef][ISI][Medline]
  31. Linden DR, Chen JX, Gershon MD, Sharkey KA, and Mawe GM. Serotonin availability is increased in mucosa of guinea pigs with TNBS-induced colitis. Am J Physiol Gastrointest Liver Physiol 285: G207–G216, 2003.[Abstract/Free Full Text]
  32. Liu MT, Rayport S, Jiang Y, Murphy DL, and Gershon MD. Expression and function of 5-HT3 receptors in the enteric neurons of mice lacking the serotonin transporter. Am J Physiol Gastrointest Liver Physiol 283: G1398–G1411, 2002.[Abstract/Free Full Text]
  33. Lovshin J and Drucker DJ. New frontiers in the biology of GLP-2. Regul Pept 90: 27–32, 2000.[CrossRef][ISI][Medline]
  34. MacNaughton WK, Lowe SS, and Cushing K. Role of nitric oxide in inflammation-induced suppression of secretion in a mouse model of acute colitis. Am J Physiol Gastrointest Liver Physiol 275: G1353–G1360, 1998.[Abstract/Free Full Text]
  35. Magro F, Vieira-Coelho MA, Fraga S, Serrao MP, Veloso FT, Ribeiro T, and Soares-da-Silva P. Impaired synthesis or cellular storage of norepinephrine, dopamine, and 5-hydroxytryptamine in human inflammatory bowel disease. Dig Dis Sci 47: 216–224, 2002.[CrossRef][ISI][Medline]
  36. Martinolle JP, Garcia-Villar R, Fioramonti J, and Bueno L. Altered contractility of circular and longitudinal muscle in TNBS-inflamed guinea pig ileum. Am J Physiol Gastrointest Liver Physiol 272: G1258–G1267, 1997.[Abstract/Free Full Text]
  37. Meier JJ, Nauck MA, Schmidt WE, and Gallwitz B. Gastric inhibitory polypeptide: the neglected incretin revisited. Regul Pept 107: 1–13, 2002.[CrossRef][ISI][Medline]
  38. Miceli P, Morris GP, MacNaughton WK, and Vanner S. Alterations in capsaicin-evoked electrolyte transport during the evolution of guinea pig TNBS ileitis. Am J Physiol Gastrointest Liver Physiol 282: G972–G980, 2002.[Abstract/Free Full Text]
  39. Miller LJ. Gastrointestinal hormones and receptors. In: Textbook of Gastroenterology, edited by Yamada T. Philadelphia, PA: Lippincott, Williams & Wilkins, 1999, p. 35–59.
  40. Miller MJ, Sadowska-Krowicka H, Chotinaruemol S, Kakkis JL, and Clark DA. Amelioration of chronic ileitis by nitric oxide synthase inhibition. J Pharmacol Exp Ther 264: 11–16, 1993.[Abstract]
  41. Miller MJ, Sadowska-Krowicka H, Jeng AY, Chotinaruemol S, Wong M, Clark DA, Ho W, and Sharkey KA. Substance P levels in experimental ileitis in guinea pigs: effects of misoprostol. Am J Physiol Gastrointest Liver Physiol 265: G321–G330, 1993.[Abstract/Free Full Text]
  42. Moreels TG, De Man JG, Dick JM, Nieuwendijk RJ, De Winter BY, Lefebvre RA, Herman AG, and Pelckmans PA. Effect of TNBS-induced morphological changes on pharmacological contractility of the rat ileum. Eur J Pharmacol 423: 211–222, 2001.[CrossRef][ISI][Medline]
  43. Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, and Wallace JL. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 96: 795–803, 1989.[ISI][Medline]
  44. Onaga T, Zabielski R, and Kato S. Multiple regulation of peptide YY secretion in the digestive tract. Peptides 23: 279–290, 2002.[CrossRef][ISI][Medline]
  45. Oshima S, Fujimura M, and Fukimiya M. Changes in number of serotonin-containing cells and serotonin levels in the intestinal mucosa of rats with colitis induced by dextran sodium sulfate. Histochem Cell Biol 112: 257–263, 1999.[CrossRef][ISI][Medline]
  46. Pan H and Gershon MD. Activation of intrinsic afferent pathways in submucosal ganglia of the guinea pig small intestine. J Neurosci 20: 3295–3309, 2000.[Abstract/Free Full Text]
  47. Peregrin AT, Ahlman H, Jodal M, and Lundgren O. Involvement of serotonin and calcium channels in the intestinal fluid secretion evoked by bile salt and cholera toxin. Br J Pharmacol 127: 887–894, 1999.[Abstract/Free Full Text]
  48. Racké K, Reimann A, Schworer H, and Kilbinger H. Regulation of 5-HT release from enterochromaffin cells. Behav Brain Res 73: 83–87, 1996.[ISI][Medline]
  49. Racké K and Schworer H. Regulation of serotonin release from the intestinal mucosa. Pharmacol Res 23: 13–25, 1991.[ISI][Medline]
  50. Rath HC, Ikeda JS, Linde HJ, Scholmerich J, Wilson KH, and Sartor RB. Varying cecal bacterial loads influences colitis and gastritis in HLA-B27 transgenic rats. Gastroenterology 116: 310–319, 1999.[ISI][Medline]
  51. Raybould HE. Visceral perception: sensory transduction in visceral afferents and nutrients. Gut 51, Suppl 1: i11–i14, 2002.
  52. Raybould HE, Cooke HJ, and Christofi FL. Sensory mechanisms: transmitters, modulators and reflexes. Neurogastroenterol Motil 16, Suppl 1: 60–63, 2004.[CrossRef]
  53. Rubin DC, Zhang H, Qian P, Lorenz RG, Hutton K, and Peters MG. Altered enteroendocrine cell expression in T cell receptor alpha chain knock-out mice. Microsc Res Tech 51: 112–120, 2000.[CrossRef][ISI][Medline]
  54. Sartor RB. Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. Am J Gastroenterol 92, Suppl 12: 5S–11S, 1997.
  55. Solcia E, Capella C, Buffa R, Usellini L, Fiocca R, Frigerio B, Tenti P, and Sessa F. The diffuse endocrine-paracrine system of the gut in health and disease: ultrastructural features. Scand J Gastroenterol Suppl 70: 25–36, 1981.[Medline]
  56. Solcia E, Capella C, Buffa R, Usellini L, Fiocca R, and Sessa F. Endocrine cells of the digestive system. In: Physiology of the Gastrointestinal Tract, edited by Johnson LR. New York: Raven, 1987, p. 111–130.
  57. Tulassay Z. Somatostatin and the gastrointestinal tract. Scand J Gastroenterol, Suppl 228: 115–121, 1998.[CrossRef]
  58. Vermillion DL, Huizinga JD, Riddell RH, and Collins SM. Altered small intestinal smooth muscle function in Crohn's disease. Gastroenterology 104: 1692–1699, 1993.[ISI][Medline]
  59. Wade PR, Chen J, Jaffe B, Kassem IS, Blakely RD, and Gershon MD. Localization and function of a 5-HT transporter in crypt epithelia of the gastrointestinal tract. J Neurosci 16: 2352–2364, 1996.[Abstract]
  60. Walsh JH. Gastrointestinal hormones. In: Physiology of the Gastrointestinal Tract, edited by Johnson LR. New York: Raven, 1987, p. 324–340.
  61. Watanabe T, Kubota Y, Sawada T, and Muto T. Distribution and quantification of somatostatin in inflammatory disease. Dis Colon Rectum 35: 488–494, 1992.[ISI][Medline]
  62. Zhu JX, Zhu XY, Owyang C, and Li Y. Intestinal serotonin acts as a paracrine substance to mediate vagal signal transmission evoked by luminal factors in the rat. J Physiol 530: 431–442, 2001.[Abstract/Free Full Text]